Markets

Adverum Biotechnologies, Inc. (ADVM): Checking the Operational Data

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decision. Now trading with a market value of 367.01M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ADVM, the company currently has 31.71 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 198.21 million in total assets, balanced by 17.22 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Adverum Biotechnologies, Inc. (ADVM) saw -10.17 million in free cash flow last quarter, representing a quarterly net change in cash of -7.81 million. Perhaps most importantly where cash movements are concerned, the company saw about -9.99 million in net operating cash flow.



Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 463,000 in total revenues. That represents a quarterly year/year change in revenues of nan in sequential terms, the ADVM saw sales decline by nan.

But what about the bottom line? After all, that’s what really matters in the end. Adverum Biotechnologies, Inc. (ADVM) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 43.38 million, this means overall earnings per share of -0.32. Note, this compares with a consensus analyst forecast of -0.31 in earnings per share for its next fiscal quarterly report.




Is Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -1.25 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Adverum Biotechnologies, Inc..

Previous ArticleNext Article

Related Post

Sanchez Energy Corporation (SN) Key Indicators And... Sanchez Energy Corporation (NYSE:SN) gained 3.30% in yesterday’s session, going up from its prior closing price of $4.85 to $5.01. The price has falle...
SCYNEXIS, Inc. (SCYX): Detailed technical analysis... SCYNEXIS, Inc. (NASDAQ:SCYX) gained 4.80% in yesterday’s session, going up from its prior closing price of $1.98 to $2.08, and has now recorded rally ...
The Gap, Inc. (GPS): More In-Depth Monitoring is N... The Gap, Inc. (NYSE:GPS)'s interesting series of developments are underway around the US stock market these days. Now trading with a market value of 1...
Looking at the Big Picture for SLM Corporation (SL... SLM Corporation (NASDAQ:SLM) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participants trying to...
Why Top Ships Inc. (TOPS) Is Being Added to Invest... It is interesting to note that Top Ships Inc. (NASDAQ:TOPS) is active and made a solid movement in the last trading day. Now trading with a market val...